Skip Navigation

Seattle Cancer Care Alliance

Fred Hutchinson Cancer Research Center
825 Eastlake Avenue E., E2-102
P.O. Box 19023
Seattle, WA 98109-1023
(206) 288-1024
(800) 804-8824
http://www.seattlecca.org

Number of Transplants Performed

This center has been performing allogeneic transplants since 1969 and has been an NMDP transplant center since February 1989.

Transplants Reported (From Jan. 2011 to Dec. 2012 as reported by the centers)       Unrelated or Related Donor Auto-
logous

(PBSC or marrow)
Total (by transplant type)
Marrow PBSC Cord
Blood
Unrelated Donor
- Adult
22 229 48 --- 299
Unrelated Donor
- Pediatric
23 9 24 --- 56
Related Donor
- Adult
27 160 0 --- 187
Related Donor
- Pediatric
19 2 1 --- 22
Autologous
- Adult
--- --- --- 413 413
Autologous
- Pediatric
--- --- --- 11 11
Total
(by cell source)
91 400 73 424 988

To find centers that perform cord blood transplants, use the Search Tool on this site.


Patient Survival Information for this Center

Fred Hutchinson Cancer Center


This center's actual 1-year survival results are above the expected rate for this center.

The survival information we have for this center includes ONLY:

  1. Patients who had their FIRST ALLOGENEIC transplant (cells from a related or unrelated donor/cord blood) during 2010, 2011 and 2012, and
  2. Who had their transplant at a U.S. transplant center, and
  3. Who had follow-up information provided by the transplant center for analysis

For this center, we have survival information for 757 patients.

The actual 1-year survival of these patients is 77.1%.

Compared to similar patients transplanted at all centers in the U.S., we expect that the 1-year survival for patients at this center to be in a range between 66.3% and 72.7%.

For help with understanding these statistics, please see Understanding Transplant Outcomes (PDF).


Transplant Results by Patient's Age, Disease Type and Stage

Seattle Cancer Care Alliance - Related

Survival by Patient's Age, Disease Type and Stage after Related Donor Transplantation

This report is based on first allogeneic transplants performed between January 2009 and December 2011 using related donors. It only includes patients with known survival status at 1-year post-transplant. In some cases, patients may have been alive at last reported follow-up that was less than one year. Those patients have not been included in this report. The first number represents the number of patients alive at one year post transplant. The second number is a total number of transplanted patients in that particular group.


Diagnosis 0-9 Yrs 10-19 Yrs 20-29 Yrs 30-39 Yrs 40-49 Yrs 50-59 Yrs 60+ Yrs Overall
Acute lymphoblastic leukemia in first complete remission 3/3 5/5 5/6 3/3 3/3 3/5 0/1 22/26
Acute lymphoblastic leukemia in second complete remission 1/3 3/5 1/2 0/1 0/1 0/1 -- 5/13
Acute lymphoblastic leukemia in third or higher complete remission, relapse, or primary induction failure -- -- -- 0/1 1/1 -- -- 1/2
Acute myelogenous leukemia in first complete remission 1/2 5/5 2/2 2/3 8/11 7/7 5/11 30/41
Acute myelogenous leukemia in second complete remission -- -- 1/2 0/1 2/2 5/5 2/3 10/13
Acute myelogenous leukemia in third or higher complete remission, relapse, or primary induction failure -- 0/1 1/1 -- 1/2 5/6 0/2 7/12
Chronic lymphocytic leukemia and other chronic leukemia -- -- -- -- 2/2 8/9 7/11 17/22
Chronic myelogenous leukemia in first chronic phase -- 2/2 -- 1/1 1/1 -- -- 4/4
Chronic myelogenous leukemia in accelerated phase or second chronic phase -- -- 0/1 0/1 1/1 2/2 -- 3/5
Chronic myelogenous leukemia in blastic phase -- -- -- -- 1/1 -- -- 1/1
Disorders of the immune system 3/5 -- -- -- -- -- -- 3/5
Histiocytic disorders 1/1 -- -- -- -- -- -- 1/1
Hodgkin lymphoma -- 3/3 5/5 5/6 1/2 1/2 -- 15/18
Inherited abnormalities of erythrocyte differentiation or function 1/1 -- -- -- -- -- -- 1/1
Multiple myeloma / Plasma cell disorder -- -- -- -- 8/9 13/14 2/3 23/26
Myelodysplastic disorders - Refractory anemia, Refractory anemia with ringed sideroblast, Refractory cytopenia with multilineage dysplasia, Refractory cytopenia with multilineage dysplasia and ringed sideroblast 1/1 -- -- 2/2 1/1 1/1 1/2 6/7
Myelodysplastic disorders - Refractory Anemia with excess blasts (with 5-9% brasts (RAEB-1) and 10-19% blasts (RAEB-2)) -- -- -- 3/3 1/1 2/5 3/4 9/13
Myelodysplastic disorders - Other MDS -- -- 1/1 -- -- -- 0/1 1/2
Myeloproliferative syndromes -- -- -- 1/1 1/1 3/5 2/3 7/10
Non-Hodgkin lymphoma -- 1/1 0/1 2/3 7/10 7/9 10/13 27/37
Other acute leukemia -- -- 1/1 -- -- 1/1 -- 2/2
Severe aplastic anemia 1/1 3/3 -- -- -- -- -- 4/4
Total 12/17 22/25 17/22 19/26 39/49 58/72 32/54 199/265

Seattle Cancer Care Alliance - Unrelated

Survival by Patient's Age, Disease Type and Stage after Unrelated Donor Transplantation

This report is based on first allogeneic transplants performed between January 2009 and December 2011 using unrelated donors. It only includes patients with known survival status at 1-year post-transplant. In some cases, patients may have been alive at last reported follow-up that was less than one year. Those patients have not been included in this report. The first number represents the number of patients alive at one year post transplant. The second number is a total number of transplanted patients in that particular group.


Diagnosis 0-9 Yrs 10-19 Yrs 20-29 Yrs 30-39 Yrs 40-49 Yrs 50-59 Yrs 60+ Yrs Overall
Acute lymphoblastic leukemia in first complete remission 4/4 8/8 4/5 3/4 5/9 5/6 2/2 31/38
Acute lymphoblastic leukemia in second complete remission 4/5 2/3 4/4 -- 2/4 1/2 -- 13/18
Acute lymphoblastic leukemia in third or higher complete remission, relapse, or primary induction failure 1/1 -- 0/1 1/1 0/1 0/1 -- 2/5
Acute myelogenous leukemia in first complete remission 2/2 2/3 4/6 10/13 15/16 10/23 19/34 62/97
Acute myelogenous leukemia in second complete remission 3/3 2/2 2/3 1/3 3/7 7/12 -- 18/30
Acute myelogenous leukemia in third or higher complete remission, relapse, or primary induction failure 1/1 1/1 1/1 -- 3/5 1/4 3/6 10/18
Auto immune diseases and other non-malignant diseases -- 1/1 1/1 -- 0/1 0/1 -- 2/4
Chronic lymphocytic leukemia and other chronic leukemia -- -- -- 1/2 1/1 5/7 8/13 15/23
Chronic myelogenous leukemia in first chronic phase 1/1 1/1 -- 2/3 3/5 -- -- 7/10
Chronic myelogenous leukemia in accelerated phase or second chronic phase -- -- -- -- 1/3 2/2 -- 3/5
Disorders of the immune system 5/6 4/5 1/1 1/1 -- -- -- 11/13
Histiocytic disorders 4/4 -- -- -- -- 1/1 -- 5/5
Inherited abnormalities of erythrocyte differentiation or function 1/1 2/2 0/1 -- -- -- -- 3/4
Inherited abnormalities of platelets 2/2 -- -- -- -- -- -- 2/2
Inherited disorders of metabolism 1/1 0/1 -- -- -- -- -- 1/2
Multiple myeloma / Plasma cell disorder -- -- -- 2/2 4/6 4/5 4/6 14/19
Myelodysplastic disorders - Refractory anemia, Refractory anemia with ringed sideroblast, Refractory cytopenia with multilineage dysplasia, Refractory cytopenia with multilineage dysplasia and ringed sideroblast 1/1 2/2 -- 2/2 2/2 6/6 4/4 17/17
Myelodysplastic disorders - Refractory Anemia with excess blasts (with 5-9% brasts (RAEB-1) and 10-19% blasts (RAEB-2)) -- -- 1/1 2/2 4/4 7/9 6/9 20/25
Myelodysplastic disorders - Other MDS -- -- 1/1 1/1 1/1 2/4 5/7 10/14
Myeloproliferative syndromes 2/2 -- 1/1 1/2 0/1 8/9 4/6 16/21
Non-Hodgkin lymphoma 1/1 0/2 1/5 2/3 5/10 10/12 11/16 30/49
Other acute leukemia 2/2 -- -- 0/1 2/2 2/2 0/1 6/8
Severe aplastic anemia 1/1 5/5 2/2 2/2 1/2 1/2 2/3 14/17
Total 36/38 30/36 23/33 31/42 52/80 72/108 68/107 312/444

Program Description:

Seattle Cancer Care Alliance (SCCA) unites doctors from Fred Hutchinson Cancer Research Center, UW Medicine, and Seattle Childrens in one world-class treatment center. SCCA's purpose is to provide state-of-the-art, patient and family centered care; support the conduct of cancer clinical research and education; enhance access to improved cancer interventions; and advance the standard of cancer care regionally and beyond. Our goal, every day, is to turn cancer patients into cancer survivors. Our purpose is to lead the world in the prevention and treatment of cancer.

Contact Information:

If you have transplant-related questions, please contact Christy Satterlee, transplant center coordinator, at (206) 288-2165 or by e-mail at csatterl@seattlecca.org.

Program Type:

Adult and Pediatric

Attending Physicians:

(Medical Doctors)

Adult -

Fredrick Appelbaum, Scott Baker, Merav Bar, Antonio Bedalov, William Bensinger, Elizabeth Budde, Aude Chaupis, Bruce Clurman, Joachim Deeg, Kristine Doney, Matthew Fero, Mary Flowers, George Georges, Ajay Gopal, Damian Green, John Hansen, Leona Holmberg, Hans-Peter Kiem, Michael Linenberger, David Maloney, Paul Martin, Suzanne McGoldrick, Marco Mielcarek, Richard Nash, Paul O'Donnell, John Pagel, Effie Petersdorf, Oliver Press, Salit Rachel, Jerald Radich, Aravind Ramakrishnan, Stanley Riddell, Steve Rosinski, Brenda Sandmaier, Bart Scott, Mohammed Sorror, F. Marc Stewart, Derek Stirewalt, Rainer Storb, Brian Till, Cameron Turtle, Houston Warren

Pediatric -

Robert Andrews, Marie Bleakely, Lauri Burroughs, Paul Carpenter, Colleen Delaney, Stephanie Lee, Soheil Meshinchi, Ann Woolfrey

Transplants Performed:

Marrow/PBSC, single cord, and double cord

Cord blood transplants performed on:

Adult and pediatric

Find research trials at this center here:

ClinicalTrials.gov

Estimated Search & Transplant Costs

The costs for a transplant vary greatly from center to center and depend on factors such as health insurance, disease type and disease stage of the patient, as well as center-specific billing policies. Examples of costs in the search and transplant include:

  • The amount and geographic location of donors tested
  • Testing needed to confirm a match
  • Processing and collecting of tissue-typing samples
  • Donor workup testing needed
  • Getting the marrow, PBSC or cord blood unit for transplant

For the best understanding of costs of transplant and follow-up for a specific transplant center, contact the center's Financial Representative.

help Explain Transplant Costs at Different Centers

Resources for financial information

If you have questions about costs and financial services at this transplant center, you can contact the center's financial representative, Debbie Stenhjem by e-mail at dstenhje@seattlecca.org or by phone at (206) 288-1101.

Financial services at this center could include:

  • Health insurance information
  • Financial assistance
  • Patient-related resources

Additional Information

Further information about this center, including the number and type of transplants performed in each of the last three years, and the support groups offered, may be found in the BMT InfoNet Transplant Center Directory:
http://www.bmtinfonet.org/transplantcenters.

BMT InfoNet (Blood & Marrow Transplant Information Network) is a nonprofit organization that provides information and emotional support to transplant patients and their families.